MARKET

PRQR

PRQR

ProQR
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.840
-0.040
-0.82%
Pre Market: 4.680 -0.16 -3.31% 08:00 03/04 EST
OPEN
4.840
PREV CLOSE
4.880
HIGH
4.930
LOW
4.650
VOLUME
2.36K
TURNOVER
--
52 WEEK HIGH
8.69
52 WEEK LOW
3.400
MARKET CAP
242.69M
P/E (TTM)
-4.2602
1D
5D
1M
3M
1Y
5Y
ProQR To Present At HC Wainwright Global Life Sciences Conference Mar. 9
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (the “Company”), a company dedicated to changing lives through the creation of
Benzinga · 1d ago
ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Global Life Sciences Conference
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IR...
GlobeNewswire · 1d ago
H.C. Wainwright Reiterates a Buy Rating on ProQR (PRQR)
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on ProQR (PRQR), with a price target of $20.00. The company's shares
SmarterAnalyst · 6d ago
ProQR EPS beats by $0.05
ProQR (PRQR): Q4 GAAP EPS of -$0.26 beats by $0.05.Cash and cash equivalents of €75.8 million, compared to €112.0 million at December 31, 2019.Press Release
Seekingalpha · 02/25 12:24
BRIEF-ProQR Announces Fourth Quarter and Full Year 2020 Operating And Financial Results
reuters.com · 02/25 12:08
ProQR (PRQR) Gets a Buy Rating from H.C. Wainwright
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on ProQR (PRQR) yesterday and set a price target of $20.00. The company's shares closed last
SmarterAnalyst · 02/24 06:41
VET, TCOM, TTM and ZI among premarket gainers
Yunhong CTI (CTIB) +77%.Dawson Geophysical (DWSN) +39%.ReTo Eco-Solutions (RETO) +31%.Vascular Biogenics (VBLT) +29%.Vinco Ventures (BBIG) +35%.Sunesis Pharmaceuticals (SNSS) +12%.Oncolytics Biotech (ONCY) +11% on encouraging pelareorep + CAR T data in sol...
Seekingalpha · 02/23 13:18
ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome
LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb 16, 2021 (GLOBE NEWSWIRE via COMTEX) -- LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE...
GlobeNewswire · 02/16 21:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PRQR. Analyze the recent business situations of ProQR through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PRQR stock price target is 20.98 with a high estimate of 32.70 and a low estimate of 12.88.
EPS
Institutional Holdings
Institutions: 87
Institutional Holdings: 29.96M
% Owned: 59.76%
Shares Outstanding: 50.14M
TypeInstitutionsShares
Increased
8
1.36M
New
24
-1.06M
Decreased
14
1.90M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.96%
Pharmaceuticals & Medical Research
-1.89%
Key Executives
Chairman - Supervisory/Independent Director
Dinko Valerio
Chairman - Management/Chief Executive Officer
Daniel De Boer
Chief Scientific Officer
Naveed Shams
Vice President/Director of Investor Relations/IR Contact Officer
Lisa Hayes
Independent Director/Supervisory Board
Bart Filius
Independent Director/Supervisory Board
Theresa Heggie
Independent Director/Supervisory Board
Alison Lawton
Independent Director/Supervisory Board
Antoine Papiernik
Independent Director/Supervisory Board
James Shannon
No Data
About PRQR
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).

Webull offers kinds of ProQR Therapeutics NV stock information, including NASDAQ:PRQR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRQR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRQR stock methods without spending real money on the virtual paper trading platform.